Cencora Inc

Cencora Inc(COR)の株式分析

$340.920

-0.477 (-0.14%)終値時点

Loading chart…
高値
343.310
始値
343.310
出来高加重平均価格
341.08
出来高
1.98M
時価総額
44.89B
安値
339.010
売買代金
674.96M
EV/EBITDA(TTM)
12.29

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

www.cencora.com

AI分析 of Cencora Inc (COR)

買い

Cencora Inc is a good buy right now due to its current price of $340.92 being below the analyst price targets, with Baird and Citi both setting targets at $370. The RSI is at 87.341, indicating strong momentum, and the company has shown a solid revenue growth trend with Q2 revenue at $78.4 billion, up 3.8% year-over-year. However, a key risk is the high debt-to-equity ratio of 361.93%, which could impact financial stability.

アナリスト評価(15)

上値余地 +21.84%
中立
7 買い
8 中立
0 売り
現在: 340.92
安値
400.00
平均
415.38
高値
440.00

RBC Capital

2026-08-19

目標株価

$330

Sector Perform

Leerink

2026-08-12

目標株価

—

アウトパフォーム

Morgan Stanley

2026-08-07

目標株価

$346

オーバーウェイト

Baird

2026-08-06

目標株価

$370

アウトパフォーム

Evercore ISI

2026-08-06

目標株価

$350

アウトパフォーム

バリュエーション指標

Cencora Inc(COR)の現在の予想PERは15.70で、5年平均は15.39です。

予想PER

適正
5年平均 P/E
15.39
現在のP/E
15.70
割高
17.62
割安
13.17

予想EV/EBITDA

適正
5年平均 EV/EBITDA
11.49
現在のEV/EBITDA
12.29
割高
13.67
割安
9.31

予想PSR

割高
5年平均 P/S
0.15
現在のP/S
0.19
割高
0.17
割安
0.12

Alphio AI による COR の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%COR

$387.16

シナリオ価格

基

基本

基本 · 50%COR

$367.49

シナリオ価格

弱

弱気

弱気 · 25%COR

$348.87

シナリオ価格

COR を保有するクジラ

T

The Woodbridge Company Limited

+ を保有COR

+13.82%

3か月リターン

W

Walgreens Boots Alliance Holdings LLC

+ を保有COR

+12.15%

3か月リターン

M

Mawer Investment Management Ltd.

+ を保有COR

+10.13%

3か月リターン

D

Diversified Trust Company, Inc.

+ を保有COR

+7.08%

3か月リターン

B

Burgundy Asset Management Ltd.

+ を保有COR

+6.08%

3か月リターン

C

Carmignac Gestion SA

+ を保有COR

+5.97%

3か月リターン

イベントタイムライン

2026-09-25 (ET)

08:30:00

Cencora Appoints Robert Sanchez as Independent Director

2026-08-12 (ET)

13:00:00

Cencora Reaffirms FY2026 EPS Guidance of $17.75 to $17.95

13:00:00

Cencora Sees FY26 Adjusted EPS of $17.75-$17.95

2026-06-15 (ET)

16:30:00

Cencora HR Executive Announces Retirement

ニュース

COR のよくある質問 — Alphio AI が回答

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

Cencora Inc is a good buy right now due to its current price of $340.92 being below the analyst price targets, with Baird and Citi both setting targets at $370. The RSI is at 87.341, indicating strong momentum, and the company has shown a solid revenue growth trend with Q2 revenue at $78.4 billion, up 3.8% year-over-year. However, a key risk is the high debt-to-equity ratio of 361.93%, which could impact financial stability.

15 analysts cover COR: 7 rate it Buy, 8 Hold and 0 Sell. The average price target is 415.38.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める